HDAC inhibitor/anti-ErbB3 mAb (Takis)

N/A

Report date: 2025/03/20 16:08:41

Base Information

Drug NameHDAC inhibitor/anti-ErbB3 mAb (Takis)
Drug Alias NameHDAC inhibitor/A3 (Takis)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsHistone deacetylase inhibitors
TargetsHistone deacetylaseReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsYes
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTakis Biotech
China Registration ClassN/A

Develop Information

Active CompaniesTakis Biotech
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A